Market Shares, Capacities, Investments, and Mergers and Acquisitions

DUBLIN, January 7, 2022 / PRNewswire / – Global Biosimilar Market Report and Forecast 2021-2026 has been added to ResearchAndMarkets.com’s offering.

The global market size for biosimilars reached a value of almost $ 16,646 million in 2020. The biosimilar market is expected to grow further between 2021 and 2026 with a CAGR of 18.1% and reach a value of almost $ 48,681 million by 2026.

A biosimilar is a biological medicine that is similar to a biological medicine (known as a reference product) previously approved by the US Food and Drug Administration (FDA). In terms of safety, purity and effectiveness, biosimilars are very comparable to the reference product, but clinically inactive components can differ significantly.

The FDA may require manufacturers to conduct a clinical study sufficient to demonstrate safety, purity, or efficacy for one or more purposes. The reference product is licensed and the biosimilar is seeking approval when approving biosimilars. It cannot be created until the patent on the reference product has expired.

The market is being driven by factors such as the increasing prevalence of chronic diseases such as cancer and diabetes, which complement the increasing demand for drugs, especially the high-priced patented drugs, and the increasing demand for biosimilars due to their economics.

The industry will also benefit from the expiration of patents on a number of biologics and a number of blockbuster drugs, which will lose their patent protection over the forecast period, as this will increase future opportunities for biosimilar manufacturers.

Regulatory approvals and other regulations that favor the introduction of biosimilars in different countries are also a major driving factor in the biosimilar market. Governments and third party payers are implementing cost-cutting programs to promote biosimilars instead of branded biologics, fueling the biosimilar market.

Another aspect driving market expansion is the growing geriatric population. The market is expected to grow due to rising FDA approvals and increasing research and development activities by major manufacturers focused on oncology.

Global market growth is fueled by a growing product pipeline and new product launches. With favorable government laws and flexible and ineffective regulations, several countries dominate the market.

Competitive landscape

The report examines, among other things, the market shares, plant turnarounds, capacities, investments and mergers and acquisitions of the main players in the industry.

Some of the key players in the marketplace examined in the report are:

  • Pfizer Inc.
  • Celltrion Inc.
  • Novartis AG
  • AMGen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Samsung Bioepis
  • Biocon Ltd.

Key topics covered:

1 Introduction

2 Report Coverage – Key Segmentation and Scope

3 Description of the report
3.1 Market definition and outlook
3.2 Properties and uses
3.3 Market Analysis
3.4 Main actors

4 key assumptions

5 Summary
5.1 Overview
5.2 main drivers
5.3 Major developments
5.4 Competitive structure
5.5 Key industrial trends

6 snapshot
6.1 Europe
6.2 Regional

7 Industry Opportunities and Challenges

8 Global Biosimilar Market Analysis
8.1 Important industry highlights
8.2 Global Biosimilar History Market (2016-2020)
8.3 Global Biosimilar Market Forecast (2021-2026)
8.4 Global Biosimilar Market By Molecules
8.4.1 Infliximab
8.4.2 Insulin glargine
8.4.3 Epoetin Alfa
8.4.4 Etanercept
8.4.5 Filgrastim
8.4.6 Somatropin
8.4.7 Rituximab
8.4.8 Follitropin alfa
8.5 Global Biosimilar Market by Type of Manufacture
8.5.1 In-house production
8.5.2 Contract manufacturing
8.6 Global Biosimilar Market By Indication
8.6.1 Autoimmune diseases
8.6.2 Blood Disease
8.6.3 Diabetes
8.6.4 Oncology
8.6.5 Lack of growth
8.6.6 Female infertility

9 regional analysis
9.1 Historical trend (2016-2020)
9.2 Forecast trend (2021-2026)
9.3 Breakdown by country

10 Market Dynamics
10.1 SWOT analysis
10.2 Porter’s Five Forces Analysis
10.3 Key indicators of demand
10.4 Key indicators for price

11 Biosimilar patent landscape
11.1 Patent landscape in the USA
11.2 Patent landscape in Europe
11.3 Patent landscape in Japan

12 Value chain analysis
12.1 Characterization of the existing innovator drug
12.2 Research and Development
12.2.1 Characterization of biosimilars
12.2.2 Development of a Unique Cell Line
12.3 Product Development
12.3.1 Preliminary test
12.3.2 Clinical Intermediate Examination (PK / PD)
12.3.3 Confirmatory clinical phase III
12.4 End product formulation
12.5 Marketing and Sales

13 Price Analysis

14 Requirements for setting up a biosimilar production facility
14.1 Manufacturing process
14.2 Raw material requirements
14.3 Raw material images
14.4 Land and construction requirements
14.5 Requirements for machines and infrastructure
14.6 Machine images
14.7 Plant layout
14.8 Packaging Requirements
14.9 Utility Requirements
14.10 Personnel requirements

15 competitive landscape
15.1 Market structure
15.2 Company Profiles

16 Events and Developments

Please visit https://www.researchandmarkets.com/r/j0n0ql for more information on this report

Media contact:

Research and Markets
Laura wood, Senior manager
[email protected]

For EST office hours, call + 1-917-300-0470. on
For US / CAN toll free call + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. on

US Fax: 646-607-1907
Fax (outside the US): + 353-1-481-1716

SOURCE Research and Markets

similar links

http://www.researchandmarkets.com

Comments are closed.